Denali Therapeutics Inc. (DNLI) stock
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.89−0.84 (-4.26%)
Close on Nov 12, 2026Market cap $3.02BP/E –Yield –
Denali Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Denali Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$530.47M. For fiscal 2025 it was -$544.16M. The highest annual figure on record is $71.25M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$544.16M | – |
| FY2024 | Dec 31, 2024 | -$479.55M | – |
| FY2023 | Dec 31, 2023 | -$179.97M | – |
| FY2022 | Dec 31, 2022 | -$330.36M | – |
| FY2021 | Dec 31, 2021 | -$287.16M | -503.0% |
| FY2020 | Dec 31, 2020 | $71.25M | – |
| FY2019 | Dec 31, 2019 | -$205.19M | – |
| FY2018 | Dec 31, 2018 | -$38.96M | – |
| FY2017 | Dec 31, 2017 | -$87.06M | – |
| FY2016 | Dec 31, 2016 | -$85.96M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$126.97M | – |
| Q1 FY2026 | Mar 31, 2026 | -$134.51M | – |
| Q4 FY2025 | Dec 31, 2025 | -$134.50M | – |
| Q3 FY2025 | Sep 30, 2025 | -$134.49M | – |
| Q2 FY2025 | Jun 30, 2025 | -$131.92M | – |
| Q1 FY2025 | Mar 31, 2025 | -$143.26M | – |
| Q4 FY2024 | Dec 31, 2024 | -$127.99M | – |
| Q3 FY2024 | Sep 30, 2024 | -$121.35M | – |
| Q2 FY2024 | Jun 30, 2024 | -$114.65M | -166.4% |
| Q1 FY2024 | Mar 31, 2024 | -$115.55M | – |
| Q4 FY2023 | Dec 31, 2023 | -$130.40M | – |
| Q3 FY2023 | Sep 30, 2023 | -$111.58M | – |
| Q2 FY2023 | Jun 30, 2023 | $172.77M | – |
| Q1 FY2023 | Mar 31, 2023 | -$110.77M | – |
| Q4 FY2022 | Dec 31, 2022 | -$101.25M | – |
| Q3 FY2022 | Sep 30, 2022 | -$105.35M | – |
| Q2 FY2022 | Jun 30, 2022 | -$59.34M | – |
| Q1 FY2022 | Mar 31, 2022 | -$64.42M | – |
| Q4 FY2021 | Dec 31, 2021 | -$75.03M | -130.5% |
| Q3 FY2021 | Sep 30, 2021 | -$83.41M | – |
| Q2 FY2021 | Jun 30, 2021 | -$59.61M | – |
| Q1 FY2021 | Mar 31, 2021 | -$69.11M | – |
| Q4 FY2020 | Dec 31, 2020 | $246.20M | – |
| Q3 FY2020 | Sep 30, 2020 | -$57.96M | – |
| Q2 FY2020 | Jun 30, 2020 | -$59.13M | – |
| Q1 FY2020 | Mar 31, 2020 | -$57.86M | – |
| Q4 FY2019 | Dec 31, 2019 | -$55.70M | -172.2% |
| Q3 FY2019 | Sep 30, 2019 | -$48.27M | – |
| Q2 FY2019 | Jun 30, 2019 | -$61.12M | – |
| Q1 FY2019 | Mar 31, 2019 | -$40.11M | – |
| Q4 FY2018 | Dec 31, 2018 | $77.10M | – |
| Q3 FY2018 | Sep 30, 2018 | -$35.64M | – |
| Q2 FY2018 | Jun 30, 2018 | -$55.53M | – |
| Q1 FY2018 | Mar 31, 2018 | -$24.89M | – |
See a number that looks wrong?